Poor Digestion and Gut Health: An unbalanced gut microbiome, frequent bloating, or sluggish digestion may impair nutrient ...

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules ...

In connection with the offering, the Company will issue 1,180,877 shares of common stock (or pre-funded warrants to purchase shares of common stock) at a purchase price of $3.60 per share, priced ...

“We are thrilled to have submitted our response to the FDA ahead of schedule, addressing their clear requests with comprehensive data and completed toxicology studies. We remain fully committed to ...

The Company was notified by the Hearings Panel of its determination to delist the Company’s common stock effective today. Lipella is disappointed by this decision—particularly in light of the fact ...

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules ...

BRIDGETOWN, Barbados, June 20, 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group (EHG), a global pharmaceutical company, and The ...

The Consolidation remains subject to the final approval of the TSX-V. Additional details regarding the Consolidation can be found in the Company’s news release dated May 15, 2025 available under the ...

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care These data demonstrate Roche's commitment to providing options ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

SeaStar Medical Holding Corporation (the “Company” or “SeaStar Medical”) (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing ...

“Traditional deep-plane facelifts focus on SMAS and ligaments,” said Dr. Lee. “But in patients with fibrotic skin or heavy soft tissue, results may fall short. By targeting deeper structures, we ...